301201.SZ · 诚达药业
China A-shares · RS rating 7 · As of 2026-10-14
| Price | 27.95 CNY |
|---|---|
| 1-day change | -4.3% |
| RS rating (overall / 1M / 3M / 12M) | 7 / 6 / 21 / 57 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 14 / 9 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -0.8% |
| Distance from 52-week high | +55.5% |
| Market cap (USD) | $696.2M |